Feed CYTK
CY

Cytokinetics

CYTK · NASDAQ

$67.56 -1.40% (-$0.96)
1M -12.36%
Market Cap $8.41B
P/E Ratio -
Div. Yield -
ROE -
Piotroski F-Score Weak
1/9
Valuation
0 /100
Expensive
P/S 118.47x
P/E N/A
EV/FFO N/A
Growth
8 /100
Declining
Rev. growth 2.36%
EPS growth N/A
Book val. growth N/A
Profitability
20 /100
Weak
Gross margin 84.97%
FCF margin 818.37%
Net margin 1,259.87%
Quality
1 /100
Poor
ROIC 39.33%
Asset turnover 0.04x
ROA 46.45%
Debt
43 /100
Moderate
Current ratio 6.66x
Int. coverage -6.68x
Debt/Equity N/A
Stability
40 /100
Moderate
Beta 0.36x
Profitable years 0
Rev. volatility 234.30%

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Ask StockBot about CYTK
Online

About the company

Cytokinetics, Incorporated is an American biotechnology company specializing in the development of therapeutic approaches aimed at improving muscle function in patients with heart and muscle diseases. The company develops innovative drug candidates targeting the regulation of muscle proteins, which can help treat conditions such as heart failure, amyotrophic lateral sclerosis (ALS), and other muscle disorders. Cytokinetics focuses on providing new treatment options for patients for whom current therapies are insufficiently effective.

Sector

Healthcare

Industry

Biotechnology

CEO

Robert I. Blum

Employees

673

Headquarters

South San Francisco

Upcoming events

04 NOV

Earnings

Upcoming earnings report

43d

We use essential cookies to run the website and optional analytics cookies to measure usage. See our Privacy Policy.